Cannabidiol and SARS-CoV-2 Infection.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 07 02 2022
accepted: 02 03 2022
entrez: 11 4 2022
pubmed: 12 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness.

Identifiants

pubmed: 35401543
doi: 10.3389/fimmu.2022.870787
pmc: PMC8987006
doi:

Substances chimiques

PPAR gamma 0
Spike Glycoprotein, Coronavirus 0
beta Catenin 0
spike protein, SARS-CoV-2 0
Cannabidiol 19GBJ60SN5
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

870787

Informations de copyright

Copyright © 2022 Vallée.

Déclaration de conflit d'intérêts

The author declares that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Références

J Med Chem. 2017 Mar 9;60(5):1620-1637
pubmed: 28074653
Sci Adv. 2022 Feb 25;8(8):eabi6110
pubmed: 35050692
Front Pharmacol. 2020 Nov 06;11:589438
pubmed: 33240092
J Biomol Struct Dyn. 2021 Jun;39(9):3387-3395
pubmed: 32364041
Cannabis Cannabinoid Res. 2020 Jun 05;5(2):121-131
pubmed: 32656344
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118
pubmed: 28250664
Aging (Albany NY). 2020 Nov 22;12(22):22425-22444
pubmed: 33221759
Cannabis Cannabinoid Res. 2021 Dec 16;:
pubmed: 34918945
Sci Rep. 2021 Jan 14;11(1):1462
pubmed: 33446817
J Clin Immunol. 2021 Feb;41(2):303-314
pubmed: 33188624
Molecules. 2020 Apr 29;25(9):
pubmed: 32365556
Pharmacol Ther. 2017 Jul;175:133-150
pubmed: 28232276
N Engl J Med. 2020 Jun 4;382(23):2261-2264
pubmed: 32433861
Br J Pharmacol. 2020 Nov;177(21):4967-4970
pubmed: 32519753
J Autoimmun. 2020 Nov;114:102512
pubmed: 32646770
iScience. 2020 Jul 24;23(7):101301
pubmed: 32629422
Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):853-866
pubmed: 28981597
Endocrinology. 2003 Jun;144(6):2201-7
pubmed: 12746275
Cannabis Cannabinoid Res. 2020 Feb 27;5(1):12-31
pubmed: 32322673
Hum Genomics. 2021 Jan 29;15(1):8
pubmed: 33514423
J Cell Mol Med. 2020 Nov;24(21):12869-12872
pubmed: 33058425
Dev Cell. 2020 Jun 8;53(5):514-529.e3
pubmed: 32425701
Eur J Pharmacol. 2019 Jan 15;843:251-259
pubmed: 30481497
Diabetes Care. 2020 Jul;43(7):1427-1432
pubmed: 32409501
Eur J Pharmacol. 2012 Dec 15;697(1-3):158-64
pubmed: 23085269
Toxicol Appl Pharmacol. 2019 Nov 1;382:114713
pubmed: 31437494
Int J Mol Sci. 2017 Nov 27;18(12):
pubmed: 29186898
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
Front Immunol. 2021 Dec 22;12:732690
pubmed: 35003058
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878
pubmed: 32544429
J Immunol. 2002 Mar 15;168(6):2795-802
pubmed: 11884448
Mol Cell Endocrinol. 2021 Jan 15;520:111095
pubmed: 33253762
Eur J Pharmacol. 2018 Jul 15;831:68-76
pubmed: 29715453
Life (Basel). 2021 Mar 29;11(4):
pubmed: 33805385
Cytokine Growth Factor Rev. 2020 Jun;53:63-65
pubmed: 32467020
Nature. 1998 Jan 1;391(6662):79-82
pubmed: 9422508
Mol Psychiatry. 2022 Jan;27(1):230-248
pubmed: 33837269
Blood Adv. 2017 Jul 10;1(16):1274-1286
pubmed: 29296769
Hong Kong Med J. 2020 Jun;26(3):250.e1-251.e2
pubmed: 32362587
Front Immunol. 2016 Sep 22;7:378
pubmed: 27713747
Aging (Albany NY). 2021 Jun 11;13(11):14552-14556
pubmed: 34115612
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
J Med Virol. 2021 Jan;93(1):61-63
pubmed: 32492199
Front Immunol. 2018 Apr 13;9:745
pubmed: 29706964
Cells. 2020 May 20;9(5):
pubmed: 32443810
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 32859680
Cannabis Cannabinoid Res. 2020 Sep 02;5(3):197-201
pubmed: 32923657
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Front Pharmacol. 2021 Apr 12;12:631646
pubmed: 33912048
Aging (Albany NY). 2021 Jan 19;13(2):1571-1590
pubmed: 33465050
Crit Care. 2014 Oct 21;18(5):568
pubmed: 25331176
Environ Sci Pollut Res Int. 2021 Apr;28(16):19589-19600
pubmed: 33655480
Turk J Biol. 2021 Aug 30;45(4):570-587
pubmed: 34803455
J Histochem Cytochem. 2016 Feb;64(2):99-111
pubmed: 26538547
J Endocrinol Invest. 2020 Aug;43(8):1053-1060
pubmed: 32495299
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):809-814
pubmed: 32540733
Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900
pubmed: 31222854
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
Int J Biol Macromol. 2020 Dec 1;164:1693-1703
pubmed: 32745548
PLoS One. 2019 Oct 4;14(10):e0223430
pubmed: 31584978
Diabetes. 2020 Dec;69(12):2691-2699
pubmed: 33024003
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Phytother Res. 2021 Dec;35(12):6893-6903
pubmed: 34643000
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Int J Biol Macromol. 2021 Jan 31;168:474-485
pubmed: 33290767
F1000Res. 2019 Feb 28;8:
pubmed: 30854190
Dev Cell. 2016 Sep 26;38(6):643-55
pubmed: 27676437
Int J Mol Sci. 2020 Dec 29;22(1):
pubmed: 33383838
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Front Immunol. 2021 Apr 13;12:666693
pubmed: 33927728
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):504-10
pubmed: 18174455

Auteurs

Alexandre Vallée (A)

Department of Epidemiology-Data-Biostatistics, Delegation of Clinical Research and Innovation (DRCI), Foch Hospital, Suresnes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH